Company Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for cancer and immune-mediated diseases. The company operates within the biotechnology and immuno-oncology sectors and is primarily engaged in the discovery and development of engineered fusion protein therapeutics designed to modulate immune responses. Shattuck has historically centered its platform around bifunctional fusion proteins intended to improve immune activation while limiting toxicity associated with conventional immunotherapies.

The company’s primary value driver has been its clinical and preclinical pipeline, including programs targeting immune checkpoint and cytokine signaling pathways. Its lead development candidate has been SL-172154, an investigational therapy designed to combine CD47 blockade with SIRPα signaling modulation for hematologic malignancies. Shattuck was founded in 2016 and became publicly traded through a Nasdaq listing under the ticker STTK in 2020. Public filings and investor materials indicate the company has evolved from a broad platform-based immunotherapy developer toward a more focused oncology pipeline strategy following portfolio prioritization initiatives.

Business Operations

Shattuck Labs primarily operates as a single-segment biotechnology enterprise focused on research and development activities. Revenue generation has historically been limited and derived mainly from collaboration agreements, licensing arrangements, and interest income rather than commercialized products. According to public filings, the company’s operations are concentrated on advancing internally developed therapeutic candidates through preclinical and clinical development stages, with expenditures primarily allocated to R&D and clinical trial operations.

The company maintains research capabilities related to protein engineering and immunotherapy development and has utilized proprietary biologic engineering approaches in its therapeutic design. Operations are primarily based in the United States, with clinical trial activity involving multiple research institutions and healthcare centers. Public disclosures have referenced collaborations with contract research organizations and manufacturing partners to support development and production activities. Data regarding large-scale joint ventures or material international operating subsidiaries remains limited based on available public sources.

Strategic Position & Investments

Shattuck Labs’ strategic direction has focused on advancing targeted immunotherapy programs with differentiated mechanisms of action in oncology. Company filings and investor presentations indicate an emphasis on selectively allocating capital toward high-priority clinical assets while reducing spending on earlier-stage or non-core programs. This strategy has included workforce reductions and pipeline reprioritization measures intended to extend cash runway and concentrate resources on lead candidates.

The company has invested substantially in the development of its fusion protein platform technologies and oncology pipeline. Public disclosures have identified SL-172154 as a central strategic asset in hematologic cancer development efforts. Shattuck has also explored opportunities in immune modulation beyond traditional checkpoint inhibition approaches. Available public information does not indicate a broad portfolio of controlled subsidiaries or major acquisition activity comparable to larger biotechnology peers. Data inconclusive based on available public sources regarding significant minority investments or portfolio company holdings.

Geographic Footprint

Shattuck Labs is headquartered in Austin, Texas, and conducts the majority of its corporate and research operations within the United States. The company’s clinical development activities involve sites across multiple U.S. regions, supported by external clinical and manufacturing partners. Public filings indicate that operational infrastructure remains primarily domestic rather than globally distributed.

While the company does not maintain a large multinational commercial footprint, its clinical and scientific activities have relevance to global oncology markets. Investor materials and SEC disclosures suggest that future commercialization strategies could involve international partnerships or licensing arrangements if clinical programs advance successfully. Current evidence of extensive direct operations in Europe, Asia-Pacific, or Latin America remains limited.

Leadership & Governance

Shattuck Labs was co-founded by Taylor Schreiber, M.D., Ph.D., who has played a central role in shaping the company’s scientific and strategic direction. Leadership communications and corporate materials have emphasized disciplined capital allocation, focused oncology development, and differentiated immunotherapy engineering as core elements of the company’s operating philosophy.

Key executives and leadership figures include:

• Taylor Schreiber, M.D., Ph.D. – Chief Executive Officer and Chairman
• Andrew Neff – Chief Financial Officer
• Jasper Boshoff, M.B.B.Ch., Ph.D. – Chief Medical Officer
• Eric Fung, Ph.D. – Chief Scientific Officer

Governance oversight is provided through the company’s board of directors and reporting obligations associated with its Nasdaq listing and filings with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K and quarterly reports on Form 10-Q.